Psychosocial and quality of life assessment in kidney transplant recipients: a focus on anxiety, depression, and clinical correlates | BMC Nephrology

This study demonstrates a substantial psychosocial burden among kidney transplant recipients, with 24.3% exhibiting abnormal anxiety and 9.9% showing abnormal depression according to HADS criteria. Notably, higher anxiety scores were significantly associated with elevated serum creatinine and lower hemoglobin levels, while depressive symptoms correlated with both lower hemoglobin and longer transplant duration. Female gender, physical inactivity, and the presence of psychiatric comorbidities were associated with increased anxiety scores. Importantly, both anxiety and depression were associated with impairments in HRQoL, with the most pronounced deficits observed in the “burden of kidney disease” and mental health domains. Patients with abnormal anxiety or depression reported the lowest scores across nearly all HRQoL domains, underscoring the critical interplay between psychosocial distress and perceived well-being in this population. These findings highlight the need for routine psychological assessment and targeted interventions to improve both mental health and overall quality of life in kidney transplant recipients.

The relatively young age of our cohort and the high proportion of hypertensive ESKD are consistent with national data from Egypt, where earlier onset of ESKD and predominance of hypertension as a cause have been documented [15, 16]. All transplants in this study were from living donors, reflecting current Egyptian practice, as deceased donor transplantation remains rare due to persistent cultural and regulatory challenges [17].

The observed prevalence of anxiety in our cohort of kidney transplant recipients was 24.3% for abnormal anxiety, with an additional 13% classified as borderline, indicating that more than one-third of patients experience at least moderate anxiety symptoms post-transplant. This rate is within the wide range reported in the literature, where studies have documented anxiety prevalence between 12.5% and 50% among kidney transplant recipients, depending on assessment tools and population characteristics [18, 19]. For example, Arapaslan et al. reported anxiety in 50% of renal transplant recipients, while other cohorts have found lower rates, such as 12.5% and 11.3% in separate studies using the HADS [18]. An Iranian study using the Beck Anxiety Inventory found that 50% of kidney transplant recipients had anxiety, with 27% experiencing mild, 15.5% moderate, and 7.5% severe symptoms [19]. A Brazilian study reported that depression and anxiety symptoms were more prevalent among dialysis patients (41.7% and 32.3%, respectively) than among transplant recipients (13.3% and 20.3%, respectively), using the Beck Inventory [20]. Karaminia and colleagues found that anxiety scores were significantly lower in transplant recipients compared to HD patients, while depression scores did not differ significantly between the two groups [21].

This study identified a 9.9% prevalence of abnormal depression among kidney transplant recipients, with 14.9% classified as borderline. These rates align with HADS-based studies from Panama (11.8%) and Thailand (12.9%) [22], reflecting the tool’s specificity in excluding somatic symptoms that often inflate depression scores in medically ill populations. However, they contrast sharply with higher rates reported in studies using instruments like the Beck Depression Inventory (BDI), such as 41.4% in Japan [23] and 22.2% in China [24], where somatic complaints (e.g., fatigue, insomnia) are included in assessments. For instance, an Iranian study using BDI reported 75% depression prevalence in kidney transplant recipients [19], underscoring how methodological differences drive variability.

The lower prevalence in this Egyptian cohort compared to some Middle Eastern studies may also reflect cultural factors, such as stigma around mental health reporting or stronger familial support structures. Additionally, the cohort’s younger mean age (38.7 years) and higher education levels (47.2% secondary school) may buffer against severe depression, contrasting with older, less-educated populations in other studies [19].

This study identified female gender as a significant predictor of higher anxiety scores (B = -3.63, p < 0.001). This aligns with broader literature indicating that women are more susceptible to anxiety disorders due to biological, hormonal, and sociocultural factors [25]. In the context of KT, women may face additional stressors such as caregiving responsibilities, body image concerns related to immunosuppressive therapy (e.g., weight gain, hirsutism), and gender-specific disparities in healthcare access [26]. These findings underscore the need for gender-sensitive mental health screening and interventions tailored to address the unique psychosocial challenges faced by female transplant recipients.

The study identified a significant positive correlation between elevated serum creatinine levels and anxiety in kidney transplant recipients (r = 0.164, p = 0.039), with multivariate analysis confirming serum creatinine as an independent predictor of anxiety (β = 0.791, p = 0.012). This association likely operates through bidirectional pathways. Physiologically, subclinical graft dysfunction—indicated by rising creatinine—may trigger sympathetic nervous system activation, elevating cortisol and norepinephrine levels, which exacerbate anxiety and perpetuate a stress-inflammatory cycle detrimental to graft health [27]. Psychologically, patients often interpret creatinine increases as precursors to graft failure, fostering hypervigilance and catastrophic thinking [28]. This aligns with findings by Hu et al. (2021), who noted that anxiety impairs self-management behaviors critical for creatinine clearance, though their study emphasized depression’s stronger correlation with renal function [18].

This study identified a significant inverse correlation between hemoglobin levels and depressive symptoms in kidney transplant recipients (r = -0.172, p = 0.029), with lower hemoglobin independently predicting higher HADS-depression scores in regression models. This aligns with prior research showing an association between anemia and depressive symptoms, potentially mediated by factors such as fatigue, reduced physical activity, and neurocognitive changes [29]. Notably, even mild hemoglobin reductions (within normal ranges) were associated with worse mental health outcomes, suggesting a dose-dependent relationship [30]. Mechanistically, iron deficiency—common in kidney transplant recipients due to post-transplant blood loss, inflammation, and immunosuppressive drug effects—may impair dopamine and serotonin synthesis, critical neurotransmitters regulating mood [31]. Recent studies highlight iron deficiency (independent of anemia) as a driver of depressive symptoms in transplant populations, with iron’s role in mitochondrial function and oxygen delivery to limbic brain regions further linking hematologic parameters to psychological well-being [30, 32]. For instance, Kremer et al. (2024) found iron deficiency doubled the risk of major depressive symptoms in kidney transplant recipients, even after adjusting for hemoglobin levels [33].

The study identified a weak but statistically significant positive correlation between transplant duration and depression scores (HADS-D: r = 0.159, p = 0.045), suggesting that longer time post-transplant may exacerbate depressive symptoms. However, this association did not retain significance in multivariate regression analysis (p = 0.254), indicating that transplant duration itself may not directly drive depression but could interact with cumulative psychosocial or clinical stressors. For instance, prolonged exposure to immunosuppressant side effects (e.g., cosmetic changes, financial strain) and diminishing social support over time may erode coping resilience [34]. This aligns with Tsunoda et al. (2010), who found no direct link between transplant duration and depression in Japanese kidney transplant recipients, emphasizing instead the role of comorbid conditions and marital discord [23]. Conversely, Hu et al. (2021) reported that longer transplant duration correlated with poorer self-management, indirectly fueling depressive symptoms through non-adherence. The discrepancy between correlation and regression findings in this study may reflect confounding by unmeasured variables, such as evolving graft function or socioeconomic shifts [18]. Clinically, these results highlight the need for sustained mental health monitoring even in long-term kidney transplant recipients, as late-onset depression could signal unaddressed psychosocial burdens or subclinical graft dysfunction.

Although the correlations between anxiety, depression, and clinical parameters (e.g., serum creatinine, hemoglobin) reached statistical significance, the observed coefficients (r ≈ 0.16–0.17) indicate only a weak association. This suggests that, while these relationships are unlikely to be due to chance, their practical or clinical impact is limited. The findings should therefore be interpreted as hypothesis-generating rather than as evidence of robust predictive value. Further research, ideally with longitudinal designs and larger effect sizes, is needed to clarify the clinical relevance of these associations [35].

The findings of this study underscore the imperative for routine psychosocial screening integrated into standard post-transplant care protocols. Implementing validated tools like the HADS and KDQOL-36 during follow-up visits enables early identification of anxiety/depression, particularly in high-risk subgroups such as women, physically active patients, and those with psychiatric histories. Targeted interventions should include: gender-specific mental health programs addressing hormonal and caregiving stressors in female kidney transplant recipients; structured lifestyle interventions (e.g., supervised aerobic/resistance training) to mitigate anxiety linked to inactivity; and iron supplementation protocols for patients with hemoglobin < 13.5 g/dl to alleviate depressive symptoms mediated by cerebral hypoxia [36]. Multidisciplinary teams should prioritize preemptive psychiatric referrals for borderline cases (14.9% depression, 13% anxiety) to prevent progression to clinical disorders. Additionally, patient education initiatives demystifying creatinine fluctuations and digital health tools (e.g., creatinine-tracking apps with clinician feedback) could reduce hypervigilance-driven anxiety. These strategies, informed by the study’s predictors and HRQoL deficits, align with evidence showing psychosocial support improves adherence by 45% and graft survival by 25% in structured programs [37, 38]. A paradigm shift toward integrated biopsychosocial care models is essential to optimize long-term outcomes in kidney transplant recipients.

This study’s strengths include its cross-sectional design with standardized, validated tools (HADS, KDQOL-36), ensuring reliable psychosocial assessment tailored to transplant populations. The integration of clinical (e.g., serum creatinine, hemoglobin), therapeutic (immunosuppressive regimens), and psychosocial data provides a multidimensional analysis of post-transplant outcomes, addressing a critical gap in holistic care research.

However, limitations must be acknowledged. The generalizability of our findings is constrained by several factors. First, the study population was relatively young, predominantly male, and largely urban-based, which may not represent the full spectrum of kidney transplant recipients in other regions or healthcare systems. Second, the single-center design further limits external validity, as center-specific practices, resources, and patient demographics can influence both clinical and psychosocial outcomes. Third, socioeconomic and cultural factors—such as income, education, healthcare access, and community support—can significantly impact both mental health and transplant outcomes. Another major limitation of this study is the absence of a control group, such as patients on dialysis or healthy controls. This restricts our ability to determine whether the observed prevalence of anxiety, depression, and impaired HRQoL is specific to the post-transplant population or reflects general trends among patients with chronic illnesses. Future research should incorporate appropriate control groups to enable direct comparisons and more robust causal inferences regarding the psychosocial impact of kidney transplantation.

While efforts were made to minimize selection bias by enrolling consecutive patients during routine follow-ups, the exclusion of unstable kidney transplant recipients (e.g., recent graft failure) may underrepresent severe mental health burdens. The cross-sectional design precludes causal inference, as temporal relationships between variables (e.g., hemoglobin-depression links) remain speculative. Longitudinal studies are needed to delineate whether anxiety/depression drive graft dysfunction or vice versa. Additionally, unmeasured confounders—such as detailed socioeconomic stressors or medication side-effect profiles—may influence observed associations. Despite these constraints, the study provides actionable insights for integrating psychosocial screening into transplant care, while underscoring the need for multicenter, prospective cohorts to validate these findings.

Future research should prioritize longitudinal cohort studies to delineate causal relationships between psychosocial disorders (anxiety/depression) and clinical outcomes in kidney transplant recipients. Prospective designs tracking HADS scores, HRQoL domains, and laboratory markers (e.g., creatinine, hemoglobin) over 5–10 years could clarify whether mental health declines precede graft dysfunction or vice versa. Additionally, randomized controlled trials (RCTs) are needed to evaluate targeted interventions, such as cognitive-behavioral therapy (CBT) protocols tailored to kidney transplant recipients’ unique stressors (e.g., fear of rejection, immunosuppressant side effects) and iron supplementation regimens for patients with subclinical deficiency.

In conclusion, this study highlights the substantial impact of psychosocial disorders, particularly anxiety and depression, on the well-being of kidney transplant recipients. Nearly one-third of patients experienced clinically significant anxiety or depression, with these conditions strongly associated with poorer health-related quality of life, higher serum creatinine, and lower hemoglobin levels. Female gender, physical inactivity, psychiatric history, and elevated serum creatinine emerged as significant predictors of psychological distress. Importantly, both anxiety and depression were associated with marked impairments across all domains of HRQoL, underscoring the intricate interplay between mental health and clinical outcomes in this population. These findings emphasize the necessity of routine psychosocial screening and targeted interventions as integral components of post-transplant care. Addressing mental health alongside traditional biomedical management is essential to optimize adherence, enhance quality of life, and ultimately improve long-term outcomes for kidney transplant recipients.